Therapeutic effect of human umbilical cord blood cells on diebetic mice

Abstract

Human adult stem cell research has been paid more attention because of the compelling ethical and legal issues surrounding human embryonic stem cells. Mononuclear cells from human umbilical cord blood (MNCs) have been showed to have plasticity. In our study, human umbilical cord blood MNCs could survival in diabetic mice without using immuno-suppressive drugs and could decreased serum glucose levels at definite time period. To observe the therapeutic effect on diabetic mice of mononuclear cell from human umbilical cord blood, experimental diabetes animal model was induced in 8w kun-ming mice by a single intraperitioneal injection of streptozotocin freshly dissolved in 0.1M of citrate buffer, pH4.5; serum glucose level were observed to monitoring effect on diabetic model. Freshly isolated human umbilical cord blood cells were labeled using PKH26, then transplanted at 2×10 6 /ml via tail vein into the model animal. glucose and insulin level in serum was determined at different time point, namely, after transplantation and distribution of transplanted cells in vivo were also examined by flow cytometer and fluorescence microscope. After 4d of cell transplantation, the serum glucose level significantly decreased and the serum insulin level increased in comparison with pre-transplantation. After 14d, the serum glucose level was recovered to the pre-transplantation level but the serum insulin level decreased in comparison with 4d and became no significant difference when compared with no-transplantation STZ treated group. PKH26 positive cells were found in panaceas, spleen, liver and bone marrow of transplanted group mice at 4d, but not in above-mentioned position at 14d by flow cytometer. The result of fluorescence microscope on tissue section were also supported this consequence.

Effect of human umbilical cord blood CD34+ progenitor cells transplantation in diabetic mice

“…This result comes in conformity with that reported by others [5] as they demonstrated that after 4 days of HUCB mononuclear cells transplantation into STZ diabetic mice, serum glucose level was significantly decreased in comparison with pre-transplantation. In another study [6] diabetic mice were treated with human bone marrow stromal cells and they demonstrated that human bone marrow stromal cells lowered blood glucose levels in the treated diabetic mice relative to untreated controls (330.12 mg/dl± 20.16 SE vs 500 mg/dl±44.1 SE, P=0.0019).…”

“…We found that the improvement of hyperglycemia was reversible and relapse occurred after 3 weeks, this finding was reported by many investigators [5,8] as they demonstrated that after 14 days of improvement, serum glucose level was returned to the pre-transplantation level. Others reported that the relapse occurred in 40% of the transplanted animals after 12 weeks.…”

Human Umbilical Cord Blood as an Emerging Stem Cell Therapy for Diabetes Mellitus

“…Another study by Zhang and associates [34] also provides evidence in support of the observations of Zhao et al [17], who observed a transient blood glucose-lowering effect of HUCB mononuclear cells in streptozotocin-induced diabetic mice. These investigators injected via tail vein 2x10 6 cells into diabetic mice, and blood glucose as well as insulin levels were measured 4 days later.…”